NUVB
HealthcareNuvation Bio Inc. · Biotechnology · $2B
What is Nuvation Bio Inc.?
Nuvation Bio is a clinical-stage biopharmaceutical company focused entirely on developing novel cancer therapies. Founded in 2018 and headquartered in New York City, it has built a pipeline targeting multiple oncology pathways.
Nuvation Bio advances small-molecule drug candidates designed to disrupt tumor growth through distinct biological mechanisms. The company does not yet generate product revenue — it funds operations through capital raises while progressing candidates through clinical trials. Its pipeline spans CDK inhibition, epigenetic regulation, DNA damage repair, and a novel drug-drug conjugate platform.
Nuvation Bio was founded in 2018 and is headquartered in New York City, US.
- NUV-422 — CDK2/4/6 inhibitor for oncology
- NUV-868 — selective oral BET inhibitor
- NUV-569 — Wee1 kinase inhibitor for DNA damage repair
- Drug-drug conjugate (DDC) platform targeting PARP
Is NUVB a Good Stock to Buy?
UQS Score rates NUVB as Below Average overall.
The Growth pillar stands out as Strong, reflecting the breadth of Nuvation Bio's advancing pipeline and the potential scale of its oncology targets. The Risk pillar is rated Good, suggesting the company's financial positioning carries relatively manageable near-term risk for a pre-revenue biotech.
Quality and Moat are both rated Weak — expected for a clinical-stage company with no approved products — and Valuation is Elevated, meaning the market has already priced in considerable optimism.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does NUVB pay dividends?
No — Nuvation Bio Inc. does not currently pay a dividend.
Nuvation Bio does not pay a dividend. As a clinical-stage company with no commercial revenue, capital is directed toward advancing its oncology pipeline through clinical trials rather than returned to shareholders as income.
When does NUVB report earnings?
Nuvation Bio reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue biotech, quarterly reports focus on pipeline progress, cash runway, and operating expenses rather than sales or profit. Investors typically watch trial updates and cash position closely.
For the most recent quarter's results, visit Nuvation Bio's investor relations page directly.
NUVB Price History
-64.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Nuvation Bio Inc.?
Based on Nuvation Bio Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Nuvation Bio do?
Nuvation Bio is a clinical-stage oncology company developing small-molecule therapies that target tumor growth through mechanisms including CDK inhibition, epigenetic regulation, and DNA damage repair. It has no approved products yet and is funded through capital markets while advancing its pipeline.
Does NUVB pay dividends?
No. Nuvation Bio does not pay a dividend. Pre-revenue biotechs typically reinvest all available capital into research and clinical development rather than distributing cash to shareholders.
When does NUVB report earnings?
Nuvation Bio follows a standard quarterly reporting schedule. Because our data source does not cover specific upcoming dates, check the company's investor relations page for the latest earnings calendar.
Is NUVB a good stock to buy?
UQS Score rates NUVB as Below Average overall. Growth is Strong and Risk is Good, but Quality and Moat are Weak, and Valuation is Elevated. The complete pillar analysis is available to Pro members on UQS Score.
Is NUVB overvalued?
The UQS Valuation pillar for NUVB is rated Elevated, suggesting the current market price reflects significant future expectations. For a pre-revenue biotech, valuation is inherently forward-looking and tied to clinical trial outcomes.
What is NUVB's market cap bracket?
Nuvation Bio is classified as a small-cap stock, which is typical for clinical-stage biopharmaceutical companies that have not yet reached commercial revenue.
Who founded Nuvation Bio?
Nuvation Bio was founded in 2018 — originally under the name RePharmation Inc. — and rebranded to Nuvation Bio in April 2019. Founding details are publicly available through the company's official disclosures.
Is NUVB a long-term quality investment?
As a long-term quality indicator, UQS rates NUVB Below Average. The Strong Growth pillar signals pipeline potential, but Weak Quality and Moat scores reflect the absence of proven commercial products. Long-term quality typically improves as clinical milestones are reached.
Unlock Full NUVB Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare NUVB against clinical-stage oncology peers
- ✓Get the complete analyst-style quality breakdown in one place
Pro Analysis
NUVB — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | 31.3 | 3.7 | 17.0 | 80.0 | 67.5 | 0.0 | -0.1 |
| Apr 22, 2026 | 31.4 | 3.7 | 17.0 | 80.0 | 67.9 | 0.0 | -4.0 |
| Apr 2, 2026 | 35.4 | 3.7 | 17.0 | 100.0 | 67.9 | 0.0 | — |
NUVB — Pillar Breakdown
Quality
— 3.7/100 (25%)Nuvation Bio Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 80.0/100 (20%)Nuvation Bio Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 67.5/100 (15%)Nuvation Bio Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Nuvation Bio Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 17/100 (25%)Nuvation Bio Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for NUVB.
Score Composition
Financial Data
More Stock Analysis
How is the NUVB UQS Score Calculated?
The UQS (Unified Quality Score) for Nuvation Bio Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Nuvation Bio Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Nuvation Bio Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.